The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Just two days after starting at the FDA, the agency’s Chief Counsel Hilary Perkins is signing off, effective immediately. | ...

Following a fire at a Bayer executive’s New Jersey home earlier this month, at least eight agencies—including the Federal ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...

It’s been just six months since Zevra Therapeutics scored an FD | Niemann-Pick disease type C therapy Miplyffa became ...

Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...